Zlepšená léčba u pacientů s dlouhodobou terapií opioidů pro bolest bez rakoviny v primární péči (Opi-Prim)
Zlepšená léčba pacientů s dlouhodobou opioidní terapií na bolest bez rakáře v primární péči (OPI-PRIM)
The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:
What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?
Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.
Participants will receive a person-centred team-based treatment consisting of:
- Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
- Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
- Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.
Primary objective:
To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care
Trial design and setting:
This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).
This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.
Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Magnus Peterson, PhD, MD
- Telefonní číslo: +46702882768
- E-mail: magnus.peterson@regionuppsala.se
Studijní záloha kontaktů
- Jméno: Anna Svensson, MD
- Telefonní číslo: +46702206400
- E-mail: anna.k.svensson@uu.se
Studijní místa
-
-
Gävleborg County
-
Gävle, Gävleborg County, Švédsko
- Zatím nenabíráme
- Region Gävleborg
-
Kontakt:
- Paul Dranichnikov, MD, PhD
- Telefonní číslo: +46762175118
- E-mail: paul.dranichnikov@uu.se
-
-
Södermanland County
-
Strängnäs, Södermanland County, Švédsko
- Zatím nenabíráme
- Region Sörmland
-
Kontakt:
- Johanna Haraldsson, MD, PhD
- Telefonní číslo: +46708636813
- E-mail: johanna.haraldsson@uu.se
-
-
Uppsala County
-
Uppsala, Uppsala County, Švédsko
- Nábor
- Region Uppsala
-
Kontakt:
- Anna Svensson, MD
- Telefonní číslo: +46702206400
- E-mail: anna.k.svensson@uu.se
-
-
Örebro County
-
Örebro, Örebro County, Švédsko
- Nábor
- Region Örebro Län
-
Kontakt:
- Elsa Ekelin, MD
- Telefonní číslo: +46708395260
- E-mail: elsa.ekelin@regionorebrolan.se
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
- Able to speak Swedish or English
Exclusion Criteria:
- Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
- No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
- Using their opioids for cancer pain
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Žádný zásah: Control
Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care. |
|
|
Aktivní komparátor: Intervention
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pain interference
Časové okno: The primary outcome measure will be the difference in mean pain interference after 6 months.
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
The primary outcome measure will be the difference in mean pain interference after 6 months.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pain intensity
Časové okno: After 3, 6 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of depression
Časové okno: After 3, 6 and 12 months
|
Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of anxiety
Časové okno: After 3, 6 and 12 months
|
Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Patient satisfaction
Časové okno: After 3, 6 and 12 months
|
Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse |
After 3, 6 and 12 months
|
|
Quality of life according to the 5-level EuroQol 5D
Časové okno: After 3, 6 and 12 months
|
Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse. |
After 3, 6 and 12 months
|
|
Opioid use
Časové okno: After 3, 6 and 12 months
|
Measured with as morphine equivalents: in mg. |
After 3, 6 and 12 months
|
|
Symptoms of withdrawal
Časové okno: After 3, 6 and 12 months
|
Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse |
After 3, 6 and 12 months
|
|
Pain interference
Časové okno: After 3 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
After 3 and 12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- Opi-Prim
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .